UNLABELLED: The aim of the study was to evaluate the glycaemic response to pre- and postprandial Humalog. MATERIAL: The study involved 47 type 1 diabetic adolescents between the ages 12 and 18 (mean 15.5) and the duration of diabetes from 1 to 13 years (mean 5.16). METHODS: All patients received Humalog in intensive therapy during 3-month period: 29 persons just before the meal and 18 immediately after the meal. All patients were injected with basal insulin twice a day (Humulin N). HbA1c values were determined at the beginning and the end of study. Patients' blood glucose levels were measured preprandially and 1 and 2 hours after eating their first bite of breakfast (noted in 1, 6 and 12 week of observation). At the end of observation (after 3 months) the analysis of the blood glucose levels after pre- and postprandial administration of Humalog insulin was performed. Blood samples were obtained at -40, -20, 0, 15, 60, 90, 120, 150 and 180 minute relative to the start of the meal. RESULTS: The mean HbA1c value decreased from 8.01 to 7.63%. The patients' preprandial glucose levels 1 and 2 hours after meal were similar in two groups in each measurement (1, 6, 12 week). The pre- and postprandial glucodynamics were similar in the two groups. The number of mild hypoglycaemic episodes was slightly higher in the group receiving Humalog before meal (0.32 vs. 0.19 episodes/person/day - p<0.05). CONCLUSION: Postprandial Humalog insulin may provide good postprandial glucodynamic control because it is safe, insulin dose can be matched to the actual food intake and it is not associated with an increase in the frequency of hypoglycaemic events. The possibility of the pre- and postprandial Humalog insulin administration improves the quality of life of patients with diabetes.
RCT Entities:
UNLABELLED: The aim of the study was to evaluate the glycaemic response to pre- and postprandial Humalog. MATERIAL: The study involved 47 type 1 diabetic adolescents between the ages 12 and 18 (mean 15.5) and the duration of diabetes from 1 to 13 years (mean 5.16). METHODS: All patients received Humalog in intensive therapy during 3-month period: 29 persons just before the meal and 18 immediately after the meal. All patients were injected with basal insulin twice a day (Humulin N). HbA1c values were determined at the beginning and the end of study. Patients' blood glucose levels were measured preprandially and 1 and 2 hours after eating their first bite of breakfast (noted in 1, 6 and 12 week of observation). At the end of observation (after 3 months) the analysis of the blood glucose levels after pre- and postprandial administration of Humalog insulin was performed. Blood samples were obtained at -40, -20, 0, 15, 60, 90, 120, 150 and 180 minute relative to the start of the meal. RESULTS: The mean HbA1c value decreased from 8.01 to 7.63%. The patients' preprandial glucose levels 1 and 2 hours after meal were similar in two groups in each measurement (1, 6, 12 week). The pre- and postprandial glucodynamics were similar in the two groups. The number of mild hypoglycaemic episodes was slightly higher in the group receiving Humalog before meal (0.32 vs. 0.19 episodes/person/day - p<0.05). CONCLUSION: Postprandial Humalog insulin may provide good postprandial glucodynamic control because it is safe, insulin dose can be matched to the actual food intake and it is not associated with an increase in the frequency of hypoglycaemic events. The possibility of the pre- and postprandial Humalog insulin administration improves the quality of life of patients with diabetes.